Pharma & Life Sciences

IMIPAT Study - Parathyroid Tissue Injection - Medical University of Vienna

ClinicalTrials.gov registered a new interventional study (NCT07516990) conducted by the Medical University of Vienna investigating parathyroid tissue injection. The Phase 1 study is listed as actively recruiting and will evaluate safety and preliminary efficacy outcomes in human subjects.

Nomophobia study, Bahçeşehir University, recruiting

ClinicalTrials.gov registered a new observational study (NCT07518056) titled 'Nomophobia study' sponsored by Bahçeşehir University, Turkey. The study is currently recruiting participants and is listed as an observational study examining smartphone dependency (nomophobia). The registration makes the trial publicly accessible on ClinicalTrials.gov.

Cerebrospinal fluid kinetics of urolithin A study

NIH/NLM published a clinical trial registration on ClinicalTrials.gov (NCT07517913) for a study examining the cerebrospinal fluid pharmacokinetics of urolithin A in approximately 12 healthy participants. The single-center, open-label study will assess how urolithin A distributes into cerebrospinal fluid following oral administration.

Stroke rehab trial evaluating Environmental Mapping Tool

A stroke rehabilitation clinical trial has been registered on ClinicalTrials.gov (NCT07517120). The study evaluates an Environmental Mapping Tool as an intervention for stroke patients. The trial is now publicly listed, providing transparency on ongoing clinical research.

Metformin cream for psoriasis vulgaris, Cairo University trial

NIH/NLM registered a new clinical trial (NCT07516821) on ClinicalTrials.gov investigating topical metformin cream for treating psoriasis vulgaris. The Phase 2 study is sponsored by Cairo University in Egypt with an estimated enrollment of 60 participants. Results posting is required under FDAAA 801 for applicable trials.

Mass balance study LPM3770164 Huntington disease

The NIH National Library of Medicine registered ClinicalTrials.gov Identifier NCT07516899, a mass balance study evaluating LPM3770164 in patients with Huntington disease. Mass balance studies track drug absorption, distribution, metabolism, and excretion (ADME) to quantify material balance. The trial is listed in the US clinical trials registry.

Patient-derived organoids, breast cancer, chemotherapy resistance study

Patient-derived organoids, breast cancer, chemotherapy resistance study

ACE Surgical sutures recall due to unlicensed medical devices

Health Canada issued a Type II recall for ACE Surgical Supply® PGA Absorbable Sutures and Absorbable Gut Sutures distributed in Canada. BioHorizons Canada is conducting the recall because manufacturer ACE Surgical Supply Co. Inc. voluntarily ceased operations and discontinued its medical device licenses in Canada, resulting in unlicensed devices on the market. All lots of 17 affected catalogue numbers are subject to this recall. Healthcare providers who have distributed these sutures must cease use and contact the importer.

Nucletron B.V. Intrauterine Tube Recall - Tip Detachment

Health Canada issued a Type II medical device recall for Nucletron B.V. Intrauterine Tubes (catalog numbers 152019-00 through 126015-01) affecting 44 product lots. The recall addresses a safety concern where the tip of the 4mm diameter IU tube detached and remained within a patient during use. Healthcare providers should contact the manufacturer for additional information.

CMS Issues Guidance on New Medicaid and CHIP Funding Limits for Noncitizens

CMS issued guidance implementing new limits on federal Medicaid and CHIP matching funds for certain noncitizens under Public Law 119-21 Section 71109. States must implement system changes by October 1, 2026, including updates to eligibility systems, applications, verification, and claims processing. Exceptions exist for emergency medical conditions and coverage of lawfully residing children and pregnant women.